Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Oppenheimer Reiterates Perform Rating on Sage Therapeutics (SAGE)

August 7, 2023 4:56 PM EDT

Oppenheimer analyst Jay Olson reiterated a Perform rating and $20.00 price target on Sage Therapeutics (NASDAQ: SAGE)

The analyst comments "SAGE is focused on delivering newly-approved Zurzuvae to PPD patients while accelerating development of pipeline assets and rationalizing OpEx spending. We... More

SAGE Therapeutics (SAGE) sinks nearly 50% as trading resumes following CRL

August 7, 2023 7:12 AM EDT

SAGE Therapeutics (NASDAQ: SAGE) sinks 47% as trading resumes after FDA approval for ZURZUVAETM in postpartum depression (PPD) but a CRL for major depressive disorder (MDD).

... More